In addition, the inhibitory effects of afatinib on EMT and tumorigenesis might be associated with the ERK-VEGF/MMP9 signaling pathway, which indicated that targeting EGFR signaling pathway-related proteins was a promising strategy for AA in the treatment of HCC [32]. Here, MMP9 is linked to hepatocellular carcinoma.